Key Highlights

  • HCW Biologics regained Nasdaq compliance following a 1-for-6 reverse stock split, resolving both a bid price deficiency and an earlier stockholders' Equity shortfall, though it remains under monitoring through June 2027.
  • The company requested an FDA pre-IND meeting for HCW11-018b, a tetravalent T-cell engager targeting solid tumors, which would become its first wholly-owned oncology program if it advances to human trials.
  • Despite reporting Net Income of $3.47 million from a licensing deal with Beijing Trimmune Biotech, cash stood at just $1.23 million against $21.6 million in total liabilities, with a going-concern warning attached.

HCW Biologics Inc. (NASDAQ:HCWB) has spent 2026 doing two hard things at once: defending its Nasdaq listing and funding its laboratories. By mid-August the Miramar, Florida biotech had made progress on both.

The company designs fusion proteins - engineered molecules that bolt together two or more immune-signalling components so they work in concert. Its lead clinical asset, HCW9302, is an interleukin-2 based molecule meant to expand regulatory T cells, which damp down misdirected immune attacks on healthy tissue. It is in a Phase 1 trial in alopecia areata, an autoimmune cause of patchy hair loss.

Two developments have concentrated attention: Nasdaq confirmed in late June that HCWB had regained compliance with its minimum bid price rule, and on 23 July the company asked the US Food and Drug Administration for a pre-IND meeting on HCW11-018b.

What Happened

The listing question came first. HCW Biologics received a bid price deficiency notice on 26 March 2026 after its shares traded below US$1.00, and a Nasdaq Hearings Panel ruled on 29 May. On 29 June the Listing Qualifications staff confirmed the company had regained compliance with Listing Rule 5550(a)(2). A 1-for-6 reverse stock split, approved by shareholders on 15 June, took effect on 30 June, cutting shares outstanding from 9,581,079 to about 1,596,849.

It was the second listing problem resolved this year: in February the company confirmed it had also satisfied Nasdaq's stockholders' equity requirement, Rule 5550(b)(1).

The 23 July announcement concerned a Type B pre-IND meeting request for HCW11-018b, a tetravalent T-cell engager: one injectable molecule with four parts, including an arm that grabs tumour cells carrying tissue factor, an arm that recruits CD3-positive T cells to kill them, an IL-15 component to keep those T cells alive and a TGF-beta trap to blunt tumour immune suppression. It has cGMP Manufacturing in place and is targeting trials in the first half of 2027.

Why It Matters

For a company this size, an exchange listing is not cosmetic. A move to the over-the-counter market narrows the investor base and complicates Capital raising, so clearing both tests removes the most immediate threat to the shares.

The relief is conditional. Nasdaq imposed a discretionary panel monitor for a year from the September 2026 compliance deadline and a mandatory monitor to 17 June 2027. A further breach inside that window skips the usual cure periods and goes straight to delisting.

The pipeline news matters differently. HCW Biologics has historically monetised molecules by licensing them out; taking HCW11-018b to its own investigational new drug application would give it a wholly owned oncology programme.

The Numbers

The first quarter of 2026 was unusual. Revenue was US$6,543,001 against US$5,065 a year earlier, almost all from licensing HCW11-006 to Beijing Trimmune Biotech. That produced net income of US$3,472,480, or US$0.37 a share before the June split, versus a US$2,196,875 loss. Research and Development spending fell 15% to US$1,257,948; general and administrative costs fell 18% to US$1,833,277.

The Trimmune deal, closed 16 March, carried US$7.0 million of upfront consideration: US$3.5 million cash, netting US$2.9 million after tax, plus a US$3.5 million equity interest. HCW Biologics kept milestones, double-digit royalties and an option to reclaim Americas rights after Phase 1.

The Balance Sheet is thinner than the profit line suggests. Cash was US$1,228,879 on 31 March against total liabilities of US$21,579,779, and operations consumed US$1,575,226 in the quarter. Full-year 2025 showed revenue of US$54,232 and a net loss of US$7,959,709. Both filings carry a Going Concern warning.

Financing has been frequent and small: about US$1.5 million in February, roughly US$4.0 million priced on 21 May with E.F. Hutton as agent, and about US$1.6 million on 29 July, the last including founder and chief executive Hing C. Wong.

What It Means for the Company

The year reads as a company buying itself time. It extinguished about US$2.8 million of disputed accounts payable: a US$1.1 million mechanics Lien filed by contractor B&I was dismissed with prejudice on 26 June, and a settlement with EirGenix cut a US$1.7 million bill to US$1.2 million, paid off by 26 May.

It has also taken back its manufacturing reagents, exercising a right on 21 May to terminate Wugen's exclusive worldwide ex vivo licence to HCW9201 and HCW9206. A March paper in Science Advances described HCW9206's potential to change how CAR-T therapies are made, and management says it is seeking a commercial partner. That strategy depends on partnering at meaningful values, and only Trimmune has delivered cash at scale.

Risks Investors Should Watch

Dilution is the most immediate risk. Three warrant-heavy financings in six months mean the share count can expand well beyond the roughly 1.8 million shares implied after the July placement. The May deal alone attached warrants over 2,846,975 shares at pre-split prices, and several tranches still need Shareholder approval.

Cash cover is thin. With about US$1.2 million on hand at the end of March and quarterly operating outflows near US$1.6 million, the company depends on continued equity market access.

Clinical risk is genuine and early. The HCW9302 readout covered six patients in two dose cohorts, all with mild disease at baseline, and was called preliminary. HCW11-018b has not yet held its pre-IND meeting.

What Comes Next

HCW Biologics had not published second-quarter results as at 14 August; the first quarter was reported on 14 May.

On HCW9302, a third cohort at 8 micrograms per kilogram was being dosed as of mid-June. In that readout, all three patients in the second cohort showed at least a 25% reduction in Severity of Alopecia Tool scores four and/or nine weeks after a single subcutaneous dose, with no dose-limiting toxicities. Management wants a recommended Phase 2 dose by year-end and a fuller readout in the fourth quarter.

Also on the calendar: the FDA pre-IND outcome for HCW11-018b; a Phase 1 start for HCW11-006 in China, guided for the first half of 2027; and the 22 September deadline to evidence continued bid price compliance.

Conclusion

HCW Biologics cleared two real hurdles this year, both Nasdaq listing deficiencies resolved and a licensing deal that produced actual cash and a rare profitable quarter, but the underlying financial picture remains fragile beneath the good headlines. Cash of $1.23 million against $21.6 million in liabilities and roughly $1.6 million of quarterly operating burn means the company depends on continued access to warrant-heavy financings that keep expanding the share count. Whether HCW11-018b's pre-IND meeting goes well, and whether another Trimmune-style licensing deal materializes, will matter more than the resolved listing status in determining if this remains a going concern.